From bugs to drugs: Therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA

Antisense and Nucleic Acid Drug Development

Volumn 11, Issue 3, 2001, Pages 181-188

  Krieg, Arthur M ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; DNA; OLIGODEOXYNUCLEOTIDE DERIVATIVE;

ALLERGIC DISEASE; B LYMPHOCYTE; CANCER; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOTHERAPY; INFECTION; LYMPHOCYTE ACTIVATION; MACROPHAGE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROKARYOTE; REVIEW; TH1 CELL;

BACTERIA (MICROORGANISMS); PROKARYOTA; VERTEBRATA;

EID: 0034952872     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729001300338717     Document Type: Review

References (96)

1. Chlamydia infections and heart disease linked through antigenic mimicry
2. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA
3. Bacterial CpG-DNA triggers activation and maturation of human CD11c(-), CD123(+) dendritic cells
4. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides
5. Non-coding plasmid DNA induces IFN-γ in vivo and suppresses autoimmune encephalomyelitis
6. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-γ production in cells from allergic individuals and inhibit IgE synthesis in vitro
7. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice
8. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyper-responsiveness in mice
9. Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo
10. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice
11. Bacterial DNA-induced NK cell IFN-γ is dependent on macrophage secretion of IL-12
12. CpG oligodeoxynucleotides overcome the unresponsiveness of neonatal B cells to stimulation with the thymus-independent stimuli anti-IgM and TNP-Ficoll
13. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
14. Bacterial DNA induces NK cells to produce IFN-γ in vivo and increases the toxicity of lipopolysaccharides
15. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans
16. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
17. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells
18. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously
19. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria
20. Atopic disorders: A default pathway in the absence of infection?
21. 1 mice
22. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA
23. Interleukin-12- and γ interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice
24. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: A comparison of vaccine formulation, route, and method of administration
25. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation
26. Mechanism and function of a newly identified CpG DNA motif in human primary B cells
27. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
28. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
29. A toll-like receptor recognizes bacterial DNA
30. Oligodeoxynucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on human NK and activated T cells to induce IFN-γ production in vitro
31. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA
32. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys
33. Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN
34. Effects of CpG DNA on Th1/Th2 balance in asthma
35. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma
36. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma
37. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ
38. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming
39. CpG DNA: A pathogenic factor in systemic lupus erythematosus?
40. Uptake and localization of phosphodiester and chimeric oligodeoxynucleotides in normal and leukemic primary cells
41. Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA
42. Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible
43. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge
44. CpG motifs in bacterial DNA trigger direct B-cell activation
45. Activation of human B cells by phosphorothioate oligodeoxynucleotides
46. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants
47. Immuno-stimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines
48. Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis
49. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds
50. Lack of immune stimulation by immobilized CpG-oligodeoxynucleotide
51. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice
52. CpG DNA is an effective oral adjuvant to protein antigens in mice
53. The toll receptor family and microbial recognition
54. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA
55. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus
56. Do DNA vaccines induce autoimmune disease?
57. CpG-containing oligonucleotides are efficient adjuvants for induction of protection antiviral immune responses with T-cell peptide vaccines
58. CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice
59. Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides
60. Immunostimulatory DNA sequences function as T helper-l-promoting adjuvants
61. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: Modulation of T cell costimulation
62. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
63. Response of human monocyte-derived dendritic cells to immunostimulatory DNA
64. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract
65. Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway
66. Microbial products induce autoimmune disease by an IL-12-dependent pathway
67. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma
68. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator
69. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model
70. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells
71. Macrophages sense pathogens via DNA motifs: Induction of tumor necrosis factor-α-mediated shock
72. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
73. Macrophages ingest and are activated by bacterial DNA
74. 8+ T cells: Implications for tumor immunotherapy
75. DNA as an adjuvant: Capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen
76. Type I interferon-mediated stimulation of T cells by CpG DNA
77. Long-term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides
78. Involvement of Ets, re1 and Sp1-like proteins in lipopolysaccharide-mediated activation of the HIV-1 LTR in macrophages
79. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium boris BCG. I. Isolation, physicochemical characterization, and antitumor activity
80. Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA
81. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus
82. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-γ-dependent mechanisms
83. Unmethylated CpG motifs protect murine B lymphocytes against Fas-mediated apoptosis
84. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response
85. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
86. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma
87. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth
88. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry
89. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL
90. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway
91. CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of IκBα and IκBβ and sustained activation of nuclear factor-κ B/c-Rel
92. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA
93. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species
94. Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity
95. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice
96. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis